{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:02:31Z","timestamp":1789754551098,"version":"4.0.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.radonc.2026.111490","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:51:23Z","timestamp":1774630283000},"page":"111490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT"],"prefix":"10.1016","volume":"219","author":[{"given":"Constanza","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3275-0941","authenticated-orcid":false,"given":"Steven","family":"Tisseverasinghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneeb U","family":"Karim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanta","family":"Ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdenour","family":"Nabid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Kaldany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Redouane","family":"Bettahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre-Guy","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjory","family":"Jolicoeur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Yassa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0860-6125","authenticated-orcid":false,"given":"Maroie","family":"Barkati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Bahoric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Archambault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Villeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Mohiuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamim","family":"Niazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111490_b0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(98)05180-0","article-title":"Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial","volume":"353","author":"Dearnaley","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111490_b0010","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ijrobp.2004.01.024","article-title":"Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate","volume":"59","author":"Luxton","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111490_b0015","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s10147-016-1057-y","article-title":"A comparison of clinical outcomes between three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer","volume":"22","author":"Shimizuguchi","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111490_b0020","article-title":"The Effectiveness of Intensity Modulated Radiation Therapy versus Three-Dimensional Radiation Therapy in Prostate Cancer: a Meta-Analysis of the Literatures","volume":"11","author":"Yu","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111490_b0025","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.29983","article-title":"Intensity-modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial","volume":"122","author":"Viani","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111490_b0030","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijrobp.2010.02.040","article-title":"Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer","volume":"80","author":"Sharma","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111490_b0035","article-title":"Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: the Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie G\u00e9nito-Urinaire de Quebec led phase 3 Trial","author":"Niazi","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111490_b0040","article-title":"Conventional vs. Hypofractionated, Radiotherapy for High-Risk Prostate Cancer: 7-Year Outcomes of the Randomized, Non-Inferiority, phase 3 PCS5 Trial","volume":"114(3):S3","author":"Niazi","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111490_b0045","unstructured":"Niazi T, Nabid A, Malagon T, Tisseverasinghe S, Bettahar R, Dahmane R, et al. Hypofractionated Dose Escalation Radiotherapy for High-Risk Prostate Cancer: the survival analysis of the Prostate Cancer Study-5 (PCS-5), a GROUQ-led phase III trial. European Urology."},{"key":"10.1016\/j.radonc.2026.111490_b0050","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.7150\/jca.87626","article-title":"Gastrointestinal\/genitourinary adverse event after intensity modulated versus three-dimensional primary radiation therapy in the treatment of prostate cancer: systematic review and meta-analysis","volume":"14","author":"Guo","year":"2023","journal-title":"J Cancer"},{"key":"10.1016\/j.radonc.2026.111490_b0055","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1200\/JCO.2016.70.4189","article-title":"Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: final results of a phase III Randomized Trial","volume":"35","author":"Arcangeli","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111490_b0060","article-title":"Radiation technique and outcomes following moderately hypofractionated treatment of low risk prostate cancer: a secondary analysis of RTOG 0415","author":"Carpenter","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.radonc.2026.111490_b0065","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1200\/JCO.2018.77.9868","article-title":"Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer","volume":"36","author":"Hoffman","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111490_b0070","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.clon.2012.05.002","article-title":"Intensity-modulated radiotherapy in the treatment of prostate cancer","volume":"24","author":"Bauman","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.radonc.2026.111490_b0075","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N","article-title":"Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma","volume":"85","author":"Zelefsky","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111490_b0080","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.urology.2013.01.047","article-title":"Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus","volume":"81","author":"Kalakota","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2026.111490_b0085","first-page":"59","article-title":"What is the impact of diabetes mellitus on radiation induced acute proctitis after radical radiotherapy for adenocarcinoma prostate? a prospective longitudinal study","volume":"14","author":"Alashkham","year":"2019","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111490_b0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210514","article-title":"Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): a multicentric retrospective analysis","volume":"14","author":"Goupy","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111490_b0095","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.3390\/curroncol30070483","article-title":"Seminal Vesicle Treatment for Localized Prostate Cancer Treated with External Beam Radiotherapy","volume":"30","author":"Steed","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2026.111490_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2022.07.589","article-title":"Late Gastrointestinal and Genitourinary Toxicities of a Moderately Hypofractionated Regimen of Intensity-Modulated Proton Therapy Targeting the Prostate\/Seminal Vesicles and Pelvic Lymph Nodes for High Risk or Unfavorable Intermediate Risk Prostate Cancer","volume":"114","author":"Choo","year":"2022","journal-title":"International Journal of Radiation Oncology*Biology*Physics"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026001295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:04:50Z","timestamp":1789751090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026001295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":20,"alternative-id":["S0167814026001295"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111490","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Conventional vs. hypofractionated radiotherapy for high-risk prostate cancer (PCS5), randomized, non-inferiority, phase III trial: Post hoc analysis of radiation therapy toxicities and efficacy of IMRT compared to 3D-CRT","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111490"}}